LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

MRK

117.14

-0.03%↓

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

MRK

117.14

-0.03%↓

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

MRK

117.14

-0.03%↓

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

MRK

117.14

-0.03%↓

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

MRK

117.14

-0.03%↓

Home・Akcijų sąrašas・Avidity Biosciences Inc

Avidity Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

15.05 4.51

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.05

Max

15.05

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-63M -237M
Pardavimai	-12M 860K
Pelnas, tenkantis vienai akcijai	-1.27
Pelno marža	-27,569.884
Darbuotojai	511
EBITDA	-59M -232M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-0.1% downside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-9B 2.3B
Ankstesnė atidarymo kaina	10.54
Ankstesnė uždarymo kaina	15.05

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

25.575 / 32.65 Palaikymas ir pasipriešinimas

Avidity Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-05 23:01; UTC

Uždarbis

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

2026-03-05 21:54; UTC

Uždarbis

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

2026-03-05 21:35; UTC

Pagrindinės rinkos jėgos

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

2026-03-06 00:00; UTC

Svarbiausios naujienos

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

2026-03-05 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

2026-03-05 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-03-05 23:27; UTC

Rinkos pokalbiai

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

2026-03-05 22:54; UTC

Rinkos pokalbiai

Uždarbis

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

2026-03-05 22:50; UTC

Rinkos pokalbiai

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

2026-03-05 22:48; UTC

Uždarbis

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026-03-05 22:46; UTC

Uždarbis

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

2026-03-05 22:44; UTC

Uždarbis

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026-03-05 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-03-05 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-05 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-05 21:35; UTC

Uždarbis

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026-03-05 21:32; UTC

Uždarbis

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026-03-05 21:26; UTC

Uždarbis

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

2026-03-05 21:24; UTC

Uždarbis

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

2026-03-05 21:23; UTC

Uždarbis

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

2026-03-05 21:22; UTC

Uždarbis

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026-03-05 21:21; UTC

Uždarbis

Costco February Digitally-Enabled Sales Rose 21.8% >COST

2026-03-05 21:21; UTC

Uždarbis

Costco Total Co Comparable Sales for February Rose 7.9% >COST

2026-03-05 21:20; UTC

Uždarbis

Costco February Net Sales Were $21.69 B >COST

2026-03-05 21:20; UTC

Uždarbis

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026-03-05 21:20; UTC

Uždarbis

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026-03-05 21:19; UTC

Uždarbis

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

2026-03-05 21:18; UTC

Uždarbis

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

2026-03-05 21:18; UTC

Uždarbis

Costco 2Q Same-Store Sales Up 7.4% >COST

2026-03-05 21:15; UTC

Uždarbis

Costco 2Q EPS $4.58 >COST

Akcijų palyginimas

Kainos pokytis

Avidity Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

-0.1% į apačią

12 mėnesių prognozė

Vidutinis 72.75 USD -0.1%

Aukščiausias 75 USD

Žemiausias 72 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Avidity Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Avidity Biosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

25.575 / 32.65Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

Finansinės naujienos

Apie bendrovę Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.